2002207202 CTX 1 2 CTX 10mg/ml 0.2ml/ /d,2d 1 2 RT-PCR 1 2 1 2 P>0.05) RT-PCR CTX CTX A study on symptom model induced by Cyclophosphamide in mice Effects of Codonopsis pilosula (Dangshen) and Shenlinbaizhu Powder on the content of serum proteinum Abstract Objective TO investing thecharacteristic and classification of the syndrome model induced by cyclophosphamide (CTX) in mice. Methods The model group treatment group 1 and treatment group 2 mice were injected ip with 0.2ml per mouse per day CTX(10mg ml -1 ) and last 2 days. The treatment group 1 and treatment group 2 mice gave concentrated solution of Codonopsis pilosula (Dangshen) and Shenlinbaizhu Powder respectively by intragastric administration.and establish the nomal group which inject normal saline at the same time.test the contents of serum protein serum globulin serum albumin and to distinguish their diffrences use four physical examinations and observe pathological samples of each organ blood samples marrow samples and examine the gene of liver tissue by RT-PCR. Results Compared with the normal group mice the Serum Protein content in the model group mice has lower tendency but the serum albumin content has higher tendency; Compared with the model group mice the Serum Protein content in the two treatment groups have higer tendency,and the serum albumin content in treatment group 1 is lower, in treatment group 2 is higher. the Serum globulin content in the other three groups have higher tendency;but there are no significance in statistics(>0.05). The pathological samples blood samples marrow samples and the RT-PCR consequence have not obvious difference.conclusion Codonopsis pilosula possibly has the little or active influence to the symptom model induced by Cyclophosphamide, Shenlinbaizhu Powder possibly has stronger effect and active influence.conected with other wxperiment conclusion,we can conclude that the symptom model of mice induced by Cyclophosphamide are not pure splenic-qi-deficiency syndrome model,the concrete classification should be researched deeply. 1
2002207202 Key words: Qi-diffciency syndrome, Cyclophosphamide, Codonopsis pilosula, Shenlinbaizhu Powder, Biochemical study CTX CTX RT-PCR CTX 1 1.1 40 18.5-22.5g 4 1 2 10 1.2 10mg/mlCTX 0.2ml/ / 1.3 1 20g 2 20g 20g 20g 20g 10g 20g 10g 5g 5g 5g 30 105ml 7 1ml/ / 3d,0.5ml/ / 4d 1.4 TDL80-2B 722 UV-7504 MOTICSFC-28 SpeedFair ACB, (TP, ) 1.5 (BCG) 4.2 Brij-3,,628,, 1.6 1.6.1 1.6.2 1.6.3 1.7 1.7.1 3600 /1 10 1.7.2 2
2002207202 1 ul H2O 4 4 4 1000 1000 1000 1 1 4ul 2 2 4ul 3 4ul 4 1000ul 5 10 6 0.5cm 630nm 7 8 = / 2 ul H2O 20 20 20 1000 1000 1000 1 1 20 ul 2 2 20ul 3 20ul 4 1000ul 5 30 6 0.5cm 5500nm 7 8 = / 9 Ö-g/L 1.8 MOTICSFC 28 1.9 SPSS12.0(statistical package for sciences) (ANOVA) 2 2.1 31 1 2 1 2 P>0.05) 3
2002207202 3 x±s g/l g/l g/l 9 31.02±27.27 56.496±25.565 25.475±27.402 10 31.96±15.69 52.932±38.689 20.970±57.490 1 8 30.76±24.61 58.847±70.983 28.088±61.235 2 9 31.97±10.87 53.112±14.084 21.143±23.248 1 2.2 ( 452345) 423 545,, 1 2 2 100 C. 1 D. 2 4
2002207202 3 400 A. B. C. 1 D. 2 4, 1 2 4 100 A. B. 5
2002207202 C. 1 D. 2 5 400 A. B. C. 1 D. 2 5,, 1 2 2.3 2.3.1 5 1 2 6
2002207202 5 400 A. B. C. 1 D. 2 2.3.2 6 1 2 6 400 A. B. 7
2002207202 C. 1 D. 2 2.3.3 1 4 4 5 3 2 14 3 1 1 24 1 1 1 1 1 7 1 2 2 1 7 2.3.4 RT-PCR 8 > 1> 2> 9 Marker 1 2 8 Marker 1 2 9 8
2002207202 3 3.1 CTX CTX CTX [1] CTX [2] [3] CTX [4] CTX 3.2 CTX CTX 17 7 14 [5] CTX [6] [7] [8] [9] [10] 3.3 [11] P>0.05), [12] 1, CTX 2 3.4CTX [13] [14] 10mm/l 9
2002207202 [15] : 20mm/l3h, CTX,, 3.5 3.5.1CTX [16] 1 2 CTX 1 2 3.5.2 [17], 1 4 4 5 3 2 1 4 3 1 1 24 1 1 1 1 1 CTX 1 2 2 1 CTX CTX [18] 3.5.3 RT-PCR > 1> 2>,CTX 10
2002207202 [19] CTX 3.6 3.6.1, 4 3.6.2, 3.6.3, 3.6.4 3.6.5 3.6.6 RT-PCR 3.6.7 3.6.8 3.6.9 3.6.10 3.7 CTX CTX CTX CTX 3.8 TEAMWORK [1],,,.[J].,1996,2(5):46-49. [2].[J].,2002,16(2):91-92. [3]. /DNA[J].,1999,13(2):152-155. [4],,,. [J].,1988,12(3): 196-200. [5],,,.[J]. 2001,32(2):94. 11
2002207202 [6]. [J].,1996,16(3): 136-138. [7],,. [J].,2001,14(11):2511. [8],,,. CTXLN [J].,2004,31(2):138. [9],,,. 5 [J].,2002, 7(9):38. [10]. 75 [J].2002, 18(5):36-36. [11]. [J].2006,15(7):747-748. [12],,..[J], 2005,20(1):66-67. [13],,,.S180[J]., 2004,26(2): 93-94. [14],.[J]., 2005,15(4):246-248. [15],,,. [J].,2001,17(3):128-131. [16],,,. CD34 ^ [J].2001, 7(7) 42-44. [17]. [J]., 2006,40(7):1-4. [18],,.[J].,2005, 33(3):67-68. [19],,. [J].,2006,5(2):109-111. 12